{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:13:50Z","timestamp":1788297230633,"version":"build-2803163510"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013356","name":"Cold Spring Harbor Laboratory","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013356","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ymthe.2026.08.028","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:25:23Z","timestamp":1787181923000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antisense oligonucleotides against Il6ra ameliorate cancer cachexia in mice"],"prefix":"10.1016","author":[{"given":"Yuanyuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingtao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9024-9501","authenticated-orcid":false,"given":"Adrian R.","family":"Krainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0154-3088","authenticated-orcid":false,"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.08.028_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-associated cachexia","volume":"4","author":"Baracos","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2026.08.028_bib2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: mediators, signaling, and metabolic pathways","volume":"16","author":"Fearon","year":"2012","journal-title":"Cell Metab."},{"key":"10.1016\/j.ymthe.2026.08.028_bib3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1146\/annurev-cancerbio-030419-033642","article-title":"Cancer-Associated Cachexia.: A Systemic Consequence of Cancer Progression","volume":"4","author":"Biswas","year":"2020","journal-title":"Annu Rev Canc Biol"},{"key":"10.1016\/j.ymthe.2026.08.028_bib4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0149-2918(05)80001-3","article-title":"Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group","volume":"69","author":"Dewys","year":"1980","journal-title":"Am J Med"},{"key":"10.1016\/j.ymthe.2026.08.028_bib5","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.2147\/CMAR.S261585","article-title":"Cancer Cachexia: Definition, Staging, and Emerging Treatments","volume":"12","author":"Ni","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ymthe.2026.08.028_bib6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrclinonc.2012.209","article-title":"Understanding the mechanisms and treatment options in cancer cachexia","volume":"10","author":"Fearon","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.08.028_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000658-198807000-00001","article-title":"Cancer cachexia","volume":"208","author":"Fearon","year":"1988","journal-title":"Ann. Surg."},{"key":"10.1016\/j.ymthe.2026.08.028_bib8","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.physbeh.2010.03.011","article-title":"Hypothalamic mechanisms in cachexia","volume":"100","author":"Grossberg","year":"2010","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.ymthe.2026.08.028_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13163990","article-title":"Neural Mechanisms of Cancer Cachexia","volume":"13","author":"Olson","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2026.08.028_bib10","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1084\/jem.20111020","article-title":"Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis","volume":"208","author":"Braun","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.ymthe.2026.08.028_bib11","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/nn.4574","article-title":"Cancer-induced anorexia and malaise are mediated by CGRP neurons in the parabrachial nucleus","volume":"20","author":"Campos","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymthe.2026.08.028_bib12","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/jcsm.12077","article-title":"MAP3K11\/GDF15 axis is a critical driver of cancer cachexia","volume":"7","author":"Lerner","year":"2016","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ymthe.2026.08.028_bib13","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/s41591-020-0945-x","article-title":"Antibody-mediated inhibition of GDF15-GFRAL activity reverses cancer cachexia in mice","volume":"26","author":"Suriben","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.08.028_bib14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/jcsm.12169","article-title":"Anorexia-cachexia syndrome in hepatoma tumour-bearing rats requires the area postrema but not vagal afferents and is paralleled by increased MIC-1\/GDF15","volume":"8","author":"Borner","year":"2017","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ymthe.2026.08.028_bib15","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.neuropharm.2017.12.024","article-title":"Brainstem GLP-1 signalling contributes to cancer anorexia-cachexia syndrome in the rat","volume":"131","author":"Borner","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ymthe.2026.08.028_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108289","article-title":"Brainstem prolactin-releasing peptide contributes to cancer anorexia-cachexia syndrome in rats","volume":"180","author":"Navarro I Batista","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ymthe.2026.08.028_bib17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/SPC.0000000000000091","article-title":"Role of interleukin-6 in cachexia: therapeutic implications","volume":"8","author":"Narsale","year":"2014","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"10.1016\/j.ymthe.2026.08.028_bib18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12041-011-0027-4","article-title":"Identification of possible genetic polymorphisms involved in cancer cachexia: a systematic review","volume":"90","author":"Tan","year":"2011","journal-title":"J. Genet."},{"key":"10.1016\/j.ymthe.2026.08.028_bib19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/SPC.0b013e3283186be2","article-title":"Cachexia, survival and the acute phase response","volume":"2","author":"Stephens","year":"2008","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"10.1016\/j.ymthe.2026.08.028_bib20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00384-009-0818-8","article-title":"Serum interleukin-6 levels in colorectal cancer patients--a summary of published results","volume":"25","author":"Kn\u00fcpfer","year":"2010","journal-title":"Int. J. Colorectal Dis."},{"key":"10.1016\/j.ymthe.2026.08.028_bib21","doi-asserted-by":"crossref","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","article-title":"Role of interleukin-6 in cancer progression and therapeutic resistance","volume":"37","author":"Kumari","year":"2016","journal-title":"Tumor Biol."},{"key":"10.1016\/j.ymthe.2026.08.028_bib22","first-page":"45","article-title":"Cytokine activity in cancer-related anorexia\/cachexia: role of megestrol acetate and medroxyprogesterone acetate","volume":"25","author":"Mantovani","year":"1998","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ymthe.2026.08.028_bib23","first-page":"107","article-title":"Inhibition of experimental cancer cachexia by anti-cytokine and anti-cytokine-receptor therapy","volume":"1","author":"Strassmann","year":"1995","journal-title":"Cytokines Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.08.028_bib24","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1172\/JCI115767","article-title":"Evidence for the involvement of interleukin 6 in experimental cancer cachexia","volume":"89","author":"Strassmann","year":"1992","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.08.028_bib25","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.cmet.2016.10.010","article-title":"Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity","volume":"24","author":"Flint","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.ymthe.2026.08.028_bib26","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/bjc.1996.294","article-title":"The relationship between weight loss and interleukin 6 in non-small-cell lung cancer","volume":"73","author":"Scott","year":"1996","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2026.08.028_bib27","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/ijc.10833","article-title":"Circulating interleukin-6 predicts survival in patients with metastatic breast cancer","volume":"103","author":"Salgado","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2026.08.028_bib28","doi-asserted-by":"crossref","first-page":"R393","DOI":"10.1152\/ajpregu.00716.2007","article-title":"Interleukin-6 and cachexia in ApcMin\/+ mice","volume":"294","author":"Baltgalvis","year":"2008","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.ymthe.2026.08.028_bib29","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00424-008-0574-6","article-title":"Muscle wasting and interleukin-6-induced atrogin-I expression in the cachectic Apc ( Min\/+ ) mouse","volume":"457","author":"Baltgalvis","year":"2009","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.ymthe.2026.08.028_bib30","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/ijc.20270","article-title":"CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice","volume":"111","author":"Zaki","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2026.08.028_bib31","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/(SICI)1097-0215(19961127)68:5<637::AID-IJC14>3.0.CO;2-Z","article-title":"Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways","volume":"68","author":"Fujita","year":"1996","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2026.08.028_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024650","article-title":"The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min\/+) mouse","volume":"6","author":"White","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.08.028_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102436","article-title":"Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer","volume":"9","author":"Ando","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.08.028_bib34","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1200\/JCO.2012.44.2020","article-title":"Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia","volume":"31","author":"Ando","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ymthe.2026.08.028_bib35","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.jpainsymman.2013.01.009","article-title":"Favorable responses to tocilizumab in two patients with cancer-related cachexia","volume":"46","author":"Hirata","year":"2013","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.ymthe.2026.08.028_bib36","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/jcsm.13638","article-title":"Tocilizumab for Advanced Non-Small-Cell Lung Cancer With Concomitant Cachexia: An Observational Study","volume":"15","author":"Du","year":"2024","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ymthe.2026.08.028_bib37","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1038\/s41467-024-48971-1","article-title":"Area postrema neurons mediate interleukin-6 function in cancer cachexia","volume":"15","author":"Sun","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.08.028_bib38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0301-0082(89)90028-2","article-title":"Area postrema: chemoreceptor circumventricular organ of the medulla oblongata","volume":"32","author":"Borison","year":"1989","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ymthe.2026.08.028_bib39","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1006\/frne.1994.1012","article-title":"The area postrema and vomiting","volume":"15","author":"Miller","year":"1994","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.ymthe.2026.08.028_bib40","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/1073858407311100","article-title":"The area postrema: a brain monitor and integrator of systemic autonomic state","volume":"14","author":"Price","year":"2008","journal-title":"Neuroscientist."},{"key":"10.1016\/j.ymthe.2026.08.028_bib41","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.neuron.2020.11.010","article-title":"Area Postrema Cell Types that Mediate Nausea-Associated Behaviors","volume":"109","author":"Zhang","year":"2021","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2026.08.028_bib42","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ymthe.2026.08.028_bib43","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/rheumatology\/keu181","article-title":"Hypersensitivity reactions to tocilizumab: role of skin tests in diagnosis","volume":"53","author":"Rocchi","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ymthe.2026.08.028_bib44","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/rheumatology\/keu008","article-title":"Tocilizumab-induced leucocytoclastic vasculitis in a patient with rheumatoid arthritis","volume":"53","author":"Sakaue","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ymthe.2026.08.028_bib45","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI25424","article-title":"Antisense oligonucleotide therapy for neurodegenerative disease","volume":"116","author":"Smith","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.08.028_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0050073","article-title":"Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon","volume":"5","author":"Hua","year":"2007","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ymthe.2026.08.028_bib47","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature10485","article-title":"Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model","volume":"478","author":"Hua","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.08.028_bib48","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/nsb887","article-title":"Correction of disease-associated exon skipping by synthetic exon-specific activators","volume":"10","author":"Cartegni","year":"2003","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.ymthe.2026.08.028_bib49","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nbt.3784","article-title":"Oligonucleotide therapies for disorders of the nervous system","volume":"35","author":"Khorkova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.08.028_bib50","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-neuro-070918-050501","article-title":"Antisense Oligonucleotide Therapies for Neurodegenerative Diseases","volume":"42","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.ymthe.2026.08.028_bib51","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1006\/jmbi.2001.5080","article-title":"Assignment of homology to genome sequences using a library of hidden Markov models that represent all proteins of known structure","volume":"313","author":"Gough","year":"2001","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ymthe.2026.08.028_bib52","doi-asserted-by":"crossref","first-page":"14756","DOI":"10.1074\/jbc.M113.466169","article-title":"Minimal Interleukin 6 (IL-6) Receptor Stalk Composition for IL-6 Receptor Shedding and IL-6 Classic Signaling","volume":"288","author":"Baran","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2026.08.028_bib53","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.biochi.2015.11.005","article-title":"Modular organization of Interleukin-6 and Interleukin-11 \u03b1-receptors","volume":"119","author":"Nitz","year":"2015","journal-title":"Biochimie"},{"key":"10.1016\/j.ymthe.2026.08.028_bib54","first-page":"2101","article-title":"Hexameric Structure and Assembly of the Interleukin-6\/IL-6 \u03b1-Receptor\/gp130","volume":"300","author":"Boulanger","year":"2003","journal-title":"Csomplex"},{"key":"10.1016\/j.ymthe.2026.08.028_bib55","doi-asserted-by":"crossref","first-page":"15959","DOI":"10.1073\/pnas.232432399","article-title":"Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain","volume":"99","author":"Varghese","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.08.028_bib56","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41580-019-0126-2","article-title":"Quality and quantity control of gene expression by nonsense-mediated mRNA decay","volume":"20","author":"Kurosaki","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ymthe.2026.08.028_bib57","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/jcsm.12225","article-title":"Establishment and characterization of a novel murine model of pancreatic cancer cachexia","volume":"8","author":"Michaelis","year":"2017","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ymthe.2026.08.028_bib58","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/s41467-021-22361-3","article-title":"Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia","volume":"12","author":"Olson","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.08.028_bib59","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"The Lancet"},{"key":"10.1016\/j.ymthe.2026.08.028_bib60","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1124\/jpet.113.212407","article-title":"Pharmacology of a central nervous system delivered 2'-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates","volume":"350","author":"Rigo","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ymthe.2026.08.028_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111947","article-title":"GDF15 neutralization restores muscle function and physical performance in a mouse model of cancer cachexia","volume":"42","author":"Kim-Muller","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2026.08.028_bib62","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1017\/S0029665120007855","article-title":"Impact of musculoskeletal degradation on cancer outcomes and strategies for management in clinical practice","volume":"80","author":"Ryan","year":"2021","journal-title":"Proc. Nutr. Soc."},{"key":"10.1016\/j.ymthe.2026.08.028_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15235590","article-title":"Cancer Cachexia: New Insights and Future Directions","volume":"15","author":"Mariean","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2026.08.028_bib64","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/nmeth.2688","article-title":"Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position","volume":"10","author":"Buenrostro","year":"2013","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2026.08.028_bib65","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/jcp.10116","article-title":"Transcription factors C\/EBP-\u03b2 and -\u03b4 regulate IL-6 production in IL-1\u03b2-stimulated human enterocytes","volume":"192","author":"Hungness","year":"2002","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ymthe.2026.08.028_bib66","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13046-024-02989-x","article-title":"IL6-STAT3-C\/EBP\u03b2-IL6 positive feedback loop in tumor-associated macrophages promotes the EMT and metastasis of lung adenocarcinoma","volume":"43","author":"Hu","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.08.028_bib67","first-page":"1","article-title":"Inhibition of CEBPB Attenuates Lupus Nephritis via Regulating Pim-1 Signaling","volume":"2022","author":"Wang","year":"2022","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.ymthe.2026.08.028_bib68","first-page":"407","article-title":"The interferon signaling network and transcription factor C\/EBP-beta","volume":"4","author":"Li","year":"2007","journal-title":"Cellular & molecular immunology"},{"key":"10.1016\/j.ymthe.2026.08.028_bib69","article-title":"Megestrol acetate for treatment of anorexia-cachexia syndrome","volume":"2019","author":"Ruiz Garcia","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ymthe.2026.08.028_bib70","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMoa2409515","article-title":"Ponsegromab for the Treatment of Cancer Cachexia","volume":"391","author":"Groarke","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ymthe.2026.08.028_bib71","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nature24042","article-title":"Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15","volume":"550","author":"Hsu","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.08.028_bib72","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/nm.4392","article-title":"GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates","volume":"23","author":"Mullican","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.08.028_bib73","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/nm.4394","article-title":"GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand","volume":"23","author":"Yang","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.08.028_bib74","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/nm.4393","article-title":"The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL","volume":"23","author":"Emmerson","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.08.028_bib75","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tips.2019.10.009","article-title":"Oligonucleotides to the (Gene) Rescue: FDA Approvals 2017-2019","volume":"41","author":"R\u00fcger","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ymthe.2026.08.028_bib76","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.3233\/JND-210682","article-title":"Exon-Skipping in Duchenne Muscular Dystrophy","volume":"8","author":"Takeda","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2026.08.028_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100416","article-title":"Antisense technology: A review","volume":"296","author":"Crooke","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2026.08.028_bib78","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/nar\/gkz1132","article-title":"Hybridization-mediated off-target effects of splice-switching antisense oligonucleotides","volume":"48","author":"Scharner","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.08.028_bib79","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/oli.2009.0215","article-title":"Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicing","volume":"20","author":"Aartsma-Rus","year":"2010","journal-title":"Oligonucleotides"},{"key":"10.1016\/j.ymthe.2026.08.028_bib80","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cbf.3652","article-title":"Distinct glycolytic pathway regulation in liver, tumour and skeletal muscle of mice with cancer cachexia","volume":"39","author":"Visavadiya","year":"2021","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.ymthe.2026.08.028_bib81","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/jcsm.12360","article-title":"Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism","volume":"10","author":"Pin","year":"2019","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ymthe.2026.08.028_bib82","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/jcsm.13468","article-title":"Skeletal muscle hypertrophy rewires glucose metabolism: An experimental investigation and systematic review","volume":"15","author":"Baumert","year":"2024","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ymthe.2026.08.028_bib83","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s43440-020-00179-y","article-title":"Altered glucose metabolism and insulin resistance in cancer-induced cachexia: a sweet poison","volume":"73","author":"Masi","year":"2021","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ymthe.2026.08.028_bib84","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s42255-024-01011-0","article-title":"Activation of GPR81 by lactate drives tumour-induced cachexia","volume":"6","author":"Liu","year":"2024","journal-title":"Nat. Metab."},{"key":"10.1016\/j.ymthe.2026.08.028_bib85","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.129240","article-title":"Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging","volume":"4","author":"Mazur","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2026.08.028_bib86","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2026.08.028_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102133","article-title":"Tissue pharmacokinetics of antisense oligonucleotides","volume":"35","author":"B\u00e4ckstr\u00f6m","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.08.028_bib88","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10928-021-09761-0","article-title":"A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration","volume":"48","author":"Monine","year":"2021","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ymthe.2026.08.028_bib89","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1038\/s41467-022-32135-0","article-title":"Blocking ActRIIB and restoring appetite reverses cachexia and improves survival in mice with lung cancer","volume":"13","author":"Queiroz","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.08.028_bib90","first-page":"2290","article-title":"Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice","volume":"50","author":"Tanaka","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2026.08.028_bib91","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41586-024-08462-1","article-title":"Rapid and scalable personalized ASO screening in patient-derived organoids","volume":"638","author":"Means","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.08.028_bib92","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s13046-023-02801-2","article-title":"A patient-derived organoid-based study identified an ASO targeting SNORD14E for endometrial cancer through reducing aberrant FOXM1 Expression and beta-catenin nuclear accumulation","volume":"42","author":"Chen","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626007094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626007094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:20:15Z","timestamp":1788294015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626007094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":92,"alternative-id":["S1525001626007094"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.08.028","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antisense oligonucleotides against Il6ra ameliorate cancer cachexia in mice","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.08.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}